Phase 2 Prostate Clinical Trials
328 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 328 trials
Recruiting
Phase 1Phase 2
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Novartis Pharmaceuticals123 enrolled11 locationsNCT07226986
Recruiting
Phase 1Phase 2
Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System
Prostate Cancer
SpectraCure AB43 enrolled3 locationsNCT06807359
Recruiting
Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled579 locationsNCT03866382
Recruiting
Phase 1Phase 2
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
Prostate Cancer
AstraZeneca300 enrolled18 locationsNCT07336446
Recruiting
Phase 2
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Prostate Cancer
Astellas Pharma Global Development, Inc.218 enrolled33 locationsNCT07005154
Recruiting
Phase 1Phase 2
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Progressive Metastatic Castrate Resistant Prostate Cancer
Novartis Pharmaceuticals188 enrolled29 locationsNCT07206056
Recruiting
Phase 2
SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC
Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)
Fudan University66 enrolled3 locationsNCT07451795
Recruiting
Phase 2
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
Stage IV Prostate Cancer AJCC v8Metastatic Prostate Small Cell Neuroendocrine CarcinomaMetastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation+1 more
National Cancer Institute (NCI)30 enrolled13 locationsNCT05691465
Recruiting
Phase 2
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
Prostate CancerProstate AdenocarcinomaProstatic Neoplasms
National Cancer Institute (NCI)42 enrolled1 locationNCT05616650
Recruiting
Phase 2Phase 3
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Prostate Cancer
Novartis Pharmaceuticals443 enrolled72 locationsNCT06780670
Recruiting
Phase 1Phase 2
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
Stage IVB Prostate Cancer AJCC v8Metastatic Malignant Neoplasm in the BoneMetastatic Castration-Resistant Prostate Carcinoma+1 more
National Cancer Institute (NCI)90 enrolled32 locationsNCT04071236
Recruiting
Phase 2
Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate Cancer
Prostate CA
British Columbia Cancer Agency100 enrolled1 locationNCT06835725
Recruiting
Phase 2
Prospective Clinical Trial of 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer
First Affiliated Hospital of Fujian Medical University20 enrolled1 locationNCT07562438
Recruiting
Phase 1Phase 2
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
Recurrent Prostate Cancer
SpectraCure AB66 enrolled4 locationsNCT03067051
Recruiting
Phase 2
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
Pancreatic AdenocarcinomaPancreatic Neuroendocrine TumorGastrointestinal Neuroendocrine Tumor+4 more
University of Michigan Rogel Cancer Center66 enrolled3 locationsNCT05988918
Recruiting
Phase 2
Bipolar Androgen Therapy + Carboplatin in mCRPC
Homologous Recombination DeficiencyCastration-resistant Prostate Cancer
St Vincent's Hospital, Sydney30 enrolled1 locationNCT03522064
Recruiting
Phase 1Phase 2
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Prostate CancerNeoplasmsNeoplasms by Site+7 more
Pathos AI, Inc.252 enrolled18 locationsNCT06785636
Recruiting
Phase 2
Working Out M0 Bipolar Androgen Therapy
Prostate Cancer
Australian and New Zealand Urogenital and Prostate Cancer Trials Group69 enrolled12 locationsNCT06594926
Recruiting
Phase 2
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Prostate Cancer Clinical Trials Consortium126 enrolled2 locationsNCT06844383
Recruiting
Phase 1Phase 2
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Neoplasms, Prostate
GlaxoSmithKline85 enrolled15 locationsNCT06990880